Transparent clinical evidence coverage
Evidence and release audit
Historical collection coverage is 235/235 articles across 233 legacy medications, with all 255 catalog records preserved. Full current clinical qualification remains 0/255 monographs. Thirty bounded reviewed claims across seven records, three targeted safety notices, and one classification correction are separate scopes. Historical inclusion, source IDs, downloaded XML and software tests do not establish full clinical validity.
Historical restoration and clinical review are separate
The historical archive contains 235 article records mapped to 233 medications. The restored structured dataset contains 255 medication records from v5.1, dated 2026-08-31.
Historical source IDs identify preserved source units or rows. They are not fully atomized, evidence-qualified clinical claims and are not counted among the 30 reviewed claims.
Local complete-monograph updates remain pending for 255 records.
Documented navigation-index corrections
Zidovudine
- Class
- Antiviral
- Original class
- Antibacterial
- Statement id
- H62-NAV-ZIDOVUDINE-001
- Status
- reviewed_classification_only
- Text
- Zidovudine is an antiretroviral agent.
- Primary uses annotation
- The archived bacterial-infection use sentence is incorrect for zidovudine. See the current exact-product label for HIV-related indications.
- References
- Url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6df09f15-b102-431c-adde-d7aeef6f5d84 (opens in a new tab)
- Locator
- 12.1 Mechanism of Action; 12.4 Microbiology, Mechanism of Action
- Authority
- ViiV Healthcare labeling in DailyMed
- Source family
- RETROVIR labeling
- Retrieval receipt
- File
- zidovudine-retrovir.xml
- Url
- https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/6df09f15-b102-431c-adde-d7aeef6f5d84.xml (opens in a new tab)
- Http status
- 200
- Bytes
- 228502
- Sha256
- b6d3456a4376aef934c9607373d58d27d01e1e17675ed1b70e5cb2e9cbd14167
- Retrieved at
- 2026-11-04T19:52:20.824912+00:00
- Local snapshot
- reports/clinical62/sources/zidovudine-retrovir.xml
- Url
- https://clinicalinfo.hiv.gov/en/drugs/zidovudine/patient (opens in a new tab)
- Locator
- What is zidovudine?; first two indication bullets and linked antiretroviral guidance
- Authority
- NIH ClinicalInfo
- Source family
- NIH independently edited clinical education; refers to FDA labeling
- Retrieval receipt
- File
- zidovudine-nih.html
- Url
- https://clinicalinfo.hiv.gov/en/drugs/zidovudine/patient (opens in a new tab)
- Http status
- 200
- Bytes
- 156005
- Sha256
- f1684f59ab00c72e8baf8bcc316cde496b9977ed25e5ef9f71bde11c0a6f2743
- Retrieved at
- 2026-11-04T19:52:25.744685+00:00
- Local snapshot
- reports/clinical62/sources/zidovudine-nih.html
- Scope
- Navigation category correction only; not a full monograph or an addition to the 30 preparation/mechanism claims.
- Reviewed at
- 2026-11-04T19:58:44.772586+00:00
Clinical evidence requirements
| Requirement | Status | Finding |
|---|---|---|
| Every local clinical statement has a unique claim ID | PARTIAL | The 30 qualified reviewed statements have unique claim IDs. All 83,771 restored historical source units have traceable H51 or HIST identifiers. A historical source unit can contain multiple clinical assertions; complete atomic claim adjudication remains pending. |
| Each consequential or numeric claim has source 1 and source 2 | PARTIAL | The 30 bounded reviewed statements each have two exact-reference mappings. Historical statements are preserved with provenance but have not undergone complete dual-source verification. Same-family label copies and targeted safety navigation are not counted as new independent regimen evidence. |
| Sources identify exact section, subsection, table or product field | PARTIAL | The 30 reviewed claims retain exact source locators. Historical JSON has original file/JSON-pointer provenance; historical articles have section/DOM text-unit locators and hashes. These archival locations are not a substitute for clinical-source verification. Targeted safety notices and AEMS rows identify exact official locations. |
| Exact formulation, route, concentration, container, labeler, application and NDC are reconciled | INCOMPLETE | Selected product details support the seven bounded summaries. No complete two-source product-identity review covers every required field and presentation for a full monograph. Historical article identity matching is separate from current exact-product reconciliation. |
| DailyMed Set ID, SPL version, revision date, retrieval date and XML hash are stored | PARTIAL | The complete evidence package contains 50 core SPL XML captures plus four targeted safety/classification XML captures. Forty-eight catalog records have core selected XML. Targeted source receipts identify their versions, dates and hashes. SPL effective dates and printed label revisions remain distinct; unresolved printed revision fields are not invented. |
| Source disagreements are documented and resolved | PARTIAL | Known product, country, wording, titration, monitoring and administration conflicts are documented with bounded dispositions and visible notices. Superseded instructions remain explicitly historical. Comprehensive reconciliation of every historical statement is pending. |
| Mechanism provenance is identified | PARTIAL | The 255 historical first-look mechanisms retain their original 199 drug-specific and 56 class-level classifications and explicit unverified status. Three separately reviewed current mechanism claims have label plus scientific-source support. Historical classification alone is not independent corroboration. |
| Renal recommendations state the renal-function method | INCOMPLETE | Acyclovir structured renal tables are restored with source-specific indexed/unindexed CrCl context and missing-method annotations. Equation and weight-basis reconciliation remain incomplete. There are no newly qualified patient-specific renal recommendations. |
| Dialysis and CRRT identify modality and relevant parameters | INCOMPLETE | Historical acyclovir dialysis and CRRT rows are preserved with modality and missing-parameter annotations. Unspecified subtype, effluent rate and operating conditions are not assumed. There are no newly qualified dialysis or CRRT dosing recommendations. |
| Current FDA safety resources are checked before packaging | SCOPED CHECK COMPLETE | Fifteen FDA resources were retrieved and reviewed within the stated scope; the check completed at 2026-11-04T20:15:05.869431+00:00. All 44 rows in the two 2026 AEMS tables were reviewed, with 8 relevant rows across 7 catalog records. This does not clear all 255 drugs, every manufacturer, application, lot or historical claim. |
| Search-only records do not display unsupported claims as verified | MET FOR STATUS SEPARATION | Current reviewed claim cards remain behind the exact-product/source gate. Search links are navigation. Restored content is displayed as historical and unverified; original current/verified/passed fields describe the older source artifact only. Archived material is not promoted into verified current coverage. |
| The final audit reports actual clinical evidence coverage | MET | The audit reports 235/235 historical articles and 255 preserved catalog records separately from 30 bounded reviewed claims, seven partial summaries and zero fully qualified contemporary monographs. All 255 full updates remain pending. Software passes and source-unit counts are not clinical-coverage percentages. |
FDA safety review
Scoped resources checked | Checked 2026-11-04T20:15:05.869431+00:00
Fifteen FDA resources checked before packaging: communications, alerts, recalls, the SrLC interface, selected medication-specific notices/labeling, and both 2026 Q1/Q2 AEMS safety tables. All 44 AEMS data rows were reviewed; 8 rows mapped to 7 catalog records. This is a scoped review, not comprehensive clearance of all medications, manufacturers, applications or lots.
- This review is not an exhaustive search of all 255 drugs, all FDA applications, every manufacturer or every marketed lot.
- The SrLC database does not cover all generic ANDA labeling changes; opening its index is not a completed product-by-product review.
- The recall notice pages describe specific affected products and lots. Do not infer class-wide recalls.
- Label downloads and NDC listings do not establish FDA approval, clinical completeness or current market availability of every presentation.
- AEMS table status dates are June 4 and September 4, 2026; November retrieval is not an updated status determination for every row.
- Potential signals do not establish causality. No-action-at-that-time is not a finding of no risk. No new treatment or dosing recommendation was generated from these tables.
- FDA Leqembi earlier MRI safety communication (opens in a new tab)
- FDA Kisunla revised titration labeling (2025) (opens in a new tab)
- Drug Safety Communications (opens in a new tab)
- Drug Alerts and Statements (opens in a new tab)
- Drug Recalls (opens in a new tab)
- Drug Safety-related Labeling Changes (opens in a new tab)
- FDA Injectafer safety communication (September1,2026) (opens in a new tab)
- FDA-posted product recall announcement: Par Health/Endo argatroban (opens in a new tab)
- FDA-posted product recall announcement: Par Health dexmedetomidine (opens in a new tab)
- FDA-posted product recall announcement: American Regent epinephrine (opens in a new tab)
- FDA-posted product recall announcement: Otsuka/ICU Medical saline overwrap (opens in a new tab)
- FDA tranexamic acid medication-error safety resource (opens in a new tab)
- FDA promethazine injection labeling-update resource (opens in a new tab)
- FDA AEMS January-March 2026 potential-signal table (opens in a new tab)
- FDA AEMS April-June 2026 potential-signal table (opens in a new tab)
Documented source and product disagreements
Remdesivir
- Review ID
- DIS-REMDESIVIR-001
- Medication
- Remdesivir
- Issue
- Presentation and storage sources require separate product reconciliation.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
VEKLURY (remdesivir) injection and powder for injection (opens in a new tab)
Exact location: SPL document metadata and product-data elements; claim-specific sections are recorded on each accepted claim.
Publisher: National Library of Medicine / DailyMed; labeler-submitted U.S. SPL
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:24.060516+00:00
A retrieved label is one evidence source. Downloading an XML file does not establish an independently corroborated clinical monograph or current availability of every listed presentation.
Source 2
Remdesivir intravenous infusion for adults (opens in a new tab)
Exact location: Named preparation and administration headings as specified at each claim
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:56:57.610191+00:00
Separately authored institutional guidance, partly based on product labeling. Used only for explicitly concordant preparation statements; Irish policy and formulation-specific differences are not transferred to U.S. products. Not independent primary trial evidence.
Caspofungin (Cancidas)
- Review ID
- DIS-CASPOFUNGIN-001
- Medication
- Caspofungin (Cancidas)
- Issue
- Product-specific preparation sources are not fully concordant.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Caspofungin acetate for injection (opens in a new tab)
Exact location: SPL document metadata and product-data elements; claim-specific sections are recorded on each accepted claim.
Publisher: National Library of Medicine / DailyMed; labeler-submitted U.S. SPL
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:46:21.743973+00:00
A retrieved label is one evidence source. Downloading an XML file does not establish an independently corroborated clinical monograph or current availability of every listed presentation.
Source 2
Caspofungin intravenous infusion for adults (opens in a new tab)
Exact location: Named preparation and administration headings as specified at each claim
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:56:57.611487+00:00
Separately authored institutional guidance, partly based on product labeling. Used only for explicitly concordant preparation statements; Irish policy and formulation-specific differences are not transferred to U.S. products. Not independent primary trial evidence.
Cefepime
- Review ID
- DIS-CEFEPIME-001
- Medication
- Cefepime
- Issue
- The inherited product selection did not match the selected current source pair.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Cefepime for Injection - Sagent Pharmaceuticals (opens in a new tab)
Exact location: SPL document metadata and product-data elements; claim-specific sections are recorded on each accepted claim.
Publisher: National Library of Medicine / DailyMed; labeler-submitted U.S. SPL
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:48:41.501881+00:00
A retrieved label is one evidence source. Downloading an XML file does not establish an independently corroborated clinical monograph or current availability of every listed presentation.
Source 2
Cefepime intravenous for adults (opens in a new tab)
Exact location: Named preparation and administration headings as specified at each claim
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:56:57.611673+00:00
Separately authored institutional guidance, partly based on product labeling. Used only for explicitly concordant preparation statements; Irish policy and formulation-specific differences are not transferred to U.S. products. Not independent primary trial evidence.
Acyclovir
- Review ID
- DIS-ACYCLOVIR-001
- Medication
- Acyclovir
- Issue
- The inherited brand and product identifiers did not describe the selected current generic product.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Acyclovir Sodium Injection, Eugia US LLC (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:15.889183+00:00
Source 2
Acyclovir Sodium Injection product information (opens in a new tab)
Exact location: Product Information table; Package Insert link
Publisher: Eugia US
Source family: Eugia manufacturer product information
Retrieved: 2026-11-04
Acyclovir
- Review ID
- DIS-ACYCLOVIR-RENAL-002
- Medication
- Acyclovir
- Issue
- Renal methods, dialysis parameters and pediatric scope remain unresolved.
- Resolution
- The affected content is pending further review. This monograph will be updated in the future.
- Status
- Unresolved; future update
Source 1
Acyclovir Sodium Injection, Eugia US LLC (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:15.889183+00:00
Linezolid
- Review ID
- DIS-LINEZOLID-001
- Medication
- Linezolid
- Issue
- The inherited brand and source version required correction.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Linezolid Injection, Sandoz Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.211498+00:00
Source 2
Linezolid Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.638943+00:00
Separately authored guide citing Fresenius Kabi September 2024 and Krka July 2023 SPCs; same 2 mg/mL formulation but not evidence of exact Sandoz NDC identity. Only concordant administration and monitoring statements transferred.
Linezolid
- Review ID
- DIS-LINEZOLID-RENAL-002
- Medication
- Linezolid
- Issue
- Renal methods and patient-selection rules are not interchangeable across the reviewed sources.
- Resolution
- The affected content is pending further review. This monograph will be updated in the future.
- Status
- Unresolved; future update
Source 1
Linezolid Injection, Sandoz Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.211498+00:00
Source 2
Linezolid Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.638943+00:00
Separately authored guide citing Fresenius Kabi September 2024 and Krka July 2023 SPCs; same 2 mg/mL formulation but not evidence of exact Sandoz NDC identity. Only concordant administration and monitoring statements transferred.
Ferric carboxymaltose
- Review ID
- DIS-INJECTAFER-001
- Medication
- Ferric carboxymaltose
- Issue
- The inherited safety source was superseded by current labeling and an FDA communication.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Injectafer, American Regent Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.185362+00:00
Source 2
FDA adds boxed warning to Injectafer for symptomatic hypophosphatemia (opens in a new tab)
Exact location: What Is FDA Doing?; What Did FDA Find?; What Should Health Care Providers Do?
Publisher: U.S. FDA Drug Safety Communication
Source family: FDA postmarketing safety assessment
Retrieved: 2026-11-04T18:54:47.961615+00:00
FDA communication describes separate postmarketing assessment using FAERS/AEMS, literature and Sentinel. Same regulatory decision as updated label, but additional safety assessment beyond a label mirror.
Ferric carboxymaltose
- Review ID
- DIS-INJECTAFER-PRODUCT-002
- Medication
- Ferric carboxymaltose
- Issue
- An additional presentation has not been fully reconciled across current product data.
- Resolution
- The affected content is pending further review. This monograph will be updated in the future.
- Status
- Unresolved; future update
Source 1
Injectafer, American Regent Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.185362+00:00
Source 2
FDA approved Injectafer prescribing information, supplement 030 (opens in a new tab)
Exact location: 12.1 Mechanism of Action; 17 manufacturer information; revision 08/2026; Reference ID 5851925
Publisher: U.S. FDA
Source family: U.S. product prescribing information
Retrieved: 2026-11-04
Official approved-label reproduction of same evidence family as current DailyMed; not independent corroboration.
Ferric carboxymaltose
- Review ID
- DIS-INJECTAFER-GALWAY-003
- Medication
- Ferric carboxymaltose
- Issue
- The U.S. label and overseas institutional guide do not support an interchangeable full regimen.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope; full monograph pending
Source 1
Injectafer, American Regent Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.185362+00:00
Source 2
Iron as Ferric Carboxymaltose (Ferinject) Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.674621+00:00
Ferinject rather than U.S. Injectafer. Both are ferric carboxymaltose 50 mg iron/mL. Guide independently edited but partly label-derived. Only explicitly concordant infusion and hypersensitivity statements transferred. Different injection rates, lower-dose infusion times and cumulative-dose schedules were excluded.
Linezolid
- Review ID
- DIS-LINEZOLID-NDC-003
- Medication
- Linezolid
- Issue
- The listed carton and its contained bag use different packaging identifiers within the same product hierarchy.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for limited selected package; full monograph pending
Source 1
Linezolid Injection, Sandoz Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.211498+00:00
Source 2
Linezolid Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.638943+00:00
Separately authored guide citing Fresenius Kabi September 2024 and Krka July 2023 SPCs; same 2 mg/mL formulation but not evidence of exact Sandoz NDC identity. Only concordant administration and monitoring statements transferred.
Source 3
Exact location: Abstract: linezolid initiation-complex assay results and concluding sentence; PubMed XML PubmedArticle[MedlineCitation/PMID="9835522"]/MedlineCitation/Article/Abstract/AbstractText
Publisher: Peer reviewed scientific literature indexed by NCBI PubMed
Source family: Swaney SM et al. 1998 original in vitro experimental study
Retrieved: 2026-11-04T18:57:55.140225+00:00
Original drug-specific in vitro experiments, a distinct scientific evidence source from the prescribing-information reproduction. Authors include Pharmacia & Upjohn investigators; do not interpret independent corroboration as financial or sponsor independence. Historical mechanism evidence only; no dosing, safety-frequency or current-resistance inference.
Review finding
- Review ID
- DIS-MECHANISM-CORROBORATION-001
- Medication
- Linezolid; ferric-carboxymaltose
- Issue
- Same-family label sources were replaced with separately authored scientific documents for the published mechanisms.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Resolved for published scope
Source 1
Injectafer, American Regent Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.185362+00:00
Source 2
Linezolid Injection, Sandoz Inc (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: DailyMed / current submitted U.S. prescribing information
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:47:16.211498+00:00
Source 3
FDA adds boxed warning to Injectafer for symptomatic hypophosphatemia (opens in a new tab)
Exact location: What Is FDA Doing?; What Did FDA Find?; What Should Health Care Providers Do?
Publisher: U.S. FDA Drug Safety Communication
Source family: FDA postmarketing safety assessment
Retrieved: 2026-11-04T18:54:47.961615+00:00
FDA communication describes separate postmarketing assessment using FAERS/AEMS, literature and Sentinel. Same regulatory decision as updated label, but additional safety assessment beyond a label mirror.
Source 4
Iron as Ferric Carboxymaltose (Ferinject) Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.674621+00:00
Ferinject rather than U.S. Injectafer. Both are ferric carboxymaltose 50 mg iron/mL. Guide independently edited but partly label-derived. Only explicitly concordant infusion and hypersensitivity statements transferred. Different injection rates, lower-dose infusion times and cumulative-dose schedules were excluded.
Source 5
Linezolid Intravenous for Adults (opens in a new tab)
Exact location: Claim-specific source locators are listed with each accepted statement.
Publisher: Galway University Hospitals / Medinfo Galway
Source family: Independent institutional administration guide (Ireland)
Retrieved: 2026-11-04T18:54:48.638943+00:00
Separately authored guide citing Fresenius Kabi September 2024 and Krka July 2023 SPCs; same 2 mg/mL formulation but not evidence of exact Sandoz NDC identity. Only concordant administration and monitoring statements transferred.
Source 6
Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. (opens in a new tab)
Exact location: Abstract: first sentence (ferric hydroxide core and carbohydrate shell) and the paragraph beginning with the macromolecular complex description; PubMed XML PubmedArticle[MedlineCitation/PMID="19405553"]/MedlineCitation/Article/Abstract/AbstractText
Publisher: Peer reviewed scientific literature indexed by NCBI PubMed
Source family: Lyseng-Williamson KA et al. 2009 drug specific scientific review
Retrieved: 2026-11-04T18:57:55.140225+00:00
Separately authored drug-specific review, distinct from an FDA/DailyMed label mirror. The abstract discusses Ferinject ferric carboxymaltose chemistry; it supports this molecular mechanism but not U.S. Injectafer package identity. Historical review, not an independent new experimental study. Its administration-time and safety summaries were not used.
Source 7
Exact location: Abstract: linezolid initiation-complex assay results and concluding sentence; PubMed XML PubmedArticle[MedlineCitation/PMID="9835522"]/MedlineCitation/Article/Abstract/AbstractText
Publisher: Peer reviewed scientific literature indexed by NCBI PubMed
Source family: Swaney SM et al. 1998 original in vitro experimental study
Retrieved: 2026-11-04T18:57:55.140225+00:00
Original drug-specific in vitro experiments, a distinct scientific evidence source from the prescribing-information reproduction. Authors include Pharmacia & Upjohn investigators; do not interpret independent corroboration as financial or sponsor independence. Historical mechanism evidence only; no dosing, safety-frequency or current-resistance inference.
Rifampin
- Review ID
- DIS-RIFAMPIN-001
- Medication
- Rifampin
- Issue
- The inherited label could not be archived from its official XML endpoints.
- Resolution
- Only individually cited statements within the reviewed product scope are published. Full monograph review remains pending.
- Status
- Navigation corrected; full monograph pending
Source 1
Rifampin for Injection - Mylan Institutional LLC (opens in a new tab)
Exact location: SPL document metadata and product-data elements; claim-specific sections are recorded on each accepted claim.
Publisher: National Library of Medicine / DailyMed; labeler-submitted U.S. SPL
Source family: U.S. product prescribing information
Retrieved: 2026-11-04T18:52:15.994756+00:00
A retrieved label is one evidence source. Downloading an XML file does not establish an independently corroborated clinical monograph or current availability of every listed presentation.
Each affected record states: "This monograph will be updated in the future." A limited reviewed summary does not imply a complete monograph or comprehensive safety clearance.
View the future-update list